Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.33 EUR
Change Today -0.03 / -8.45%
Volume 0.0
4HW On Other Exchanges
Symbol
Exchange
BrsaItaliana
As of 3:36 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

molecular medicine spa (4HW) Snapshot

Open
€0.35
Previous Close
€0.36
Day High
€0.36
Day Low
€0.32
52 Week High
09/9/14 - €0.47
52 Week Low
01/12/15 - €0.28
Market Cap
137.0M
Average Volume 10 Days
3.3K
EPS TTM
--
Shares Outstanding
421.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MOLECULAR MEDICINE SPA (4HW)

Related News

No related news articles were found.

molecular medicine spa (4HW) Related Businessweek News

No Related Businessweek News Found

molecular medicine spa (4HW) Details

MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in a Phase III trial in acute leukaemia patients in first or subsequent complete remission and at high risk of relapse, suitable for haploidentical haematopoietic stem cell transplantation. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has agreements with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.

Founded in 1996

molecular medicine spa (4HW) Top Compensated Officers

Founder, Chairman, Chairman of the Scientific...
Total Annual Compensation: €750.0K
Business Development & IR Director, General M...
Total Annual Compensation: €409.0K
Director of Business Development & Strategic ...
Total Annual Compensation: €406.0K
Compensation as of Fiscal Year 2014.

molecular medicine spa (4HW) Key Developments

MolMed S.p.A. Announces Revenue Results for the First Half of 2015

MolMed S.p.A. announced revenue results for the first half of 2015. The company reported 52.5% increase in revenues in the first half of 2015 from EUR 4,703,000 to EUR 7,174,000, substantially due to activities for third parties that went from EUR 4,230,000 in the first half of 2014 to EUR 6,888,000 in the first half of 2015 thanks mainly to the agreement signed with GSK.

MolMed S.p.A. Reports Earnings Results for the Six Months Ended June 30, 2015

MolMed S.p.A. reported earnings results for the six months ended June 30, 2015. For the period, the company reported total operating revenues of EUR 7,174,000 compared to EUR 4,703,000 a year ago. Operating loss was EUR 11,099,000 compared to EUR 8,791,000 a year ago. Pre-tax loss was EUR 11,208,000 compared to EUR 9,010,000 a year ago. Loss for the period was EUR 11,208,000 compared to EUR 9,010,000 a year ago. Net cash used in operating activities was EUR 3,717,000 compared to EUR 7,322,000 a year ago. Net investment in tangible assets was EUR 2,216,000 compared to EUR 1,495,000 a year ago. Net investment in intangible assets was EUR 28,000 compared to EUR 75,000 a year ago.

MolMed S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2015

MolMed S.p.A. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total operating revenues of EUR 2,658,000 against EUR 1,405,000 a year ago. Operating loss was EUR 4,141,000 against EUR 5,159,000 a year ago. Pre-tax loss was EUR 4,232,000 against EUR 5,199,000 a year ago. Loss for the period was EUR 4,232,000 against EUR 5,199,000 a year ago. The increase in revenues is mainly due to the intensification of GMP development and production activities for third parties.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4HW:GR €0.33 EUR -0.03

4HW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4HW.
View Industry Companies
 

Industry Analysis

4HW

Industry Average

Valuation 4HW Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.2x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOLECULAR MEDICINE SPA, please visit www.molmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.